Brokers Issue Forecasts for Organigram FY2027 Earnings

Organigram Holdings Inc. (TSE:OGI) – Analysts at Atb Cap Markets issued their FY2027 EPS estimates for Organigram in a research report issued on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes anticipates that the company will post earnings of $0.08 per share for the year. The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s FY2028 earnings at $0.20 EPS.

A number of other equities analysts have also recently issued reports on OGI. Canaccord Genuity Group lowered their target price on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating for the company in a report on Monday, December 9th. ATB Capital decreased their price objective on Organigram from C$5.25 to C$3.50 in a report on Tuesday, December 17th.

Organigram Stock Performance

Shares of TSE:OGI opened at C$1.92 on Thursday. The firm has a market cap of C$237.20 million, a price-to-earnings ratio of -4.06, a PEG ratio of 0.42 and a beta of 1.13. Organigram has a 12 month low of C$1.86 and a 12 month high of C$3.95. The company’s fifty day simple moving average is C$2.24 and its 200 day simple moving average is C$2.32. The company has a quick ratio of 2.62, a current ratio of 3.36 and a debt-to-equity ratio of 3.07.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.